Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651313 | 0.96 | HDAC6 (0.47) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL6793694 | 0.95 | HDAC4 (0.50) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL6676557 | 0.91 | HDAC6 (0.49) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL29571861 | 0.89 | HDAC4 (0.60) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL8363221 | 0.85 | HDAC4 (0.46) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL20528841 | 0.76 | HDAC4 (0.54) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL29741712 | 0.76 | HDAC6 (0.49) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL21900051 | 0.75 | HDAC4 (0.53) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL21900054 | 0.74 | HDAC4 (0.55) | HDAC6HDAC1HDAC5HDAC4HDAC3 | |
| SCHEMBL19745634 | 0.74 | HDAC1 (0.83) | HDAC6HDAC1HDAC5HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | HDAC6 2119/4885HDAC1 952/4885HDAC5 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.